#DC26
LightNews LightNews
robertlufkinmd.bsky.social
Full breakdown coming on the Health Longevity Secrets podcast www.youtube.com/@RobertLufkinMD

Source: doi.org/10.2337/dc26...

#MetabolicHealth #HealthLongevitySecrets #Type2Diabetes #DiabetesRemission (6/6)
November 6, 2026 at 11:16 PM
adapubs.bsky.social
For #AmericanDiabetesMonth, we're highlighting the ADA's Standards of Care and Abridged Standards of Care

➡️ Diabetes Care in the Hospital: Standards of Care in Diabetes—2026: doi.org/10.2337/dc26-S016

➡️ Section 2: Diagnosis and Classification of Diabetes doi.org/10.2337/doc26-a016

#WeFight
Image showing a publication titled "Standards of Care in Diabetes—2026" displayed on a cover of Diabetes Care journal. The background has "American Diabetes Month" written in white text on a blue square. Below the journal is the text "16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026 doi.org/10.2337/dc26-S016" and a red button labeled "Read Now.
November 7, 2026 at 7:00 PM
adapubs.bsky.social
#ENDIAstudy children with #T1D had differences in exocrine pancreas function within the first 6 months of life with further changes after islet autoimmunity, up to 18 months before diagnosis.

Read here ➡️ doi.org/10.2337/dc26-1627

A flowchart illustrating the longitudinal changes in exocrine biomarkers in early life related to Type 1 Diabetes in the ENDIA study. It shows four stages: Birth, 0-6 months, Seroconversion, and Presymptomatic Type 1 Diabetes. Birth involves collecting serial stool and serum samples. From 0-6 months, there's a lower FE-1 in potential multiple A1ypo1 diabetes patients. During Seroconversion, there's persistent islet autoantibodies. In the Presymptomatic stage, IRT declines before diagnosis. The areas below provide additional details on biology, timing, and translation. A highlighted takeaway message reads: "Longitudinal exocrine biomarker changes precede clinical type 1 diabetes".
November 5, 2026 at 6:00 PM
adapubs.bsky.social
Among autoantibody-positive youth with overweight or obesity, BMI normalization was associated with lower stage 3 T1D risk, but observational findings do not establish causality. #T1D #TrialNet

Read here ➡️ doi.org/10.2337/dc26-1752
Comment on Martyn-Nemeth et al. Sleep Optimization to Improve Glycemic Targets in Adults With Type 1 Diabetes: A Randomized Controlled Parallel Intervention Trial
I read with great interest about the randomized trial by Martyn-Nemeth et al. (1) evaluating the remotely delivered Sleep-Opt intervention in adults with t
doi.org
November 7, 2026 at 1:20 PM
adapubs.bsky.social
In adults with #T2D, twiist use led to 16% higher time-in-range and 0.7% reduction in HbA1c.

Read here ➡️ doi.org/10.2337/dc26-1270
This image is a research poster titled "A Multicenter 13-Week Evaluation of the twist Automated Insulin Delivery in Insulin-Treated Type 2 Diabetes." It includes sections on background, objectives, participant characteristics, primary analysis, time-in-range data, and conclusions. Key results are shown in graphs, highlighting improvements in HbA1c levels and time-in-range metrics. Glucagon-like peptide 1 receptor agonist and sodium-glucose co-transporter-2 inhibitors are mentioned. The conclusion states the twist system was safe and effective. There are numerical data, percentages, and visual comparisons.
November 1, 2026 at 9:20 PM
gerbangpost.bsky.social
Karnival Deepavali ke-24 sasar 500,000 pengunjung, medan adaptasi AI
KUALA LUMPUR,. Karnival Deepavali Ke-24 (DC26) menyasarkan kehadiran lebih 500,000 pengunjung selain menjadi medan utama mempromosikan adaptasi teknologi kecerdasan buatan (AI) dalam kalangan usahawan tempatan. Menteri Digital, Gobind Singh Deo berkata, acara tahunan itu diharap terus diperluas pada masa hadapan seiring kemunculan teknologi baharu di peringkat global. “Teknologi telah berkembang dan saya rasa pasaran sekarang […]
dlvr.it
November 2, 2026 at 2:07 AM
adapubs.bsky.social
Type 1 diabetes was associated with higher risk of mortality, particularly among females. This association was attenuated among individuals diagnosed in more recent years.

Read here ➡️ doi.org/10.2337/dc26-1472
This infographic presents findings on sex-specific mortality risk in Type 1 Diabetes during advanced therapeutic care. It details a registry of 4,299 participants with a mortality rate of 131 per 100,000 person-years for those with Type 1 Diabetes, compared to 3.97 for a control group. The relative mortality risk is higher in females with a hazard ratio of 9.0, while for males, it is 2.9. The study spans from 2000-2023 with follow-up data available from 2011-2022.
November 4, 2026 at 4:45 PM
adapubs.bsky.social
In 1,105 Japanese children with #T1D, 6% used school restrooms for care, linking to higher HbA1c and spiking at high school entry. Pump/CGM use and male sex link to classroom care.

Read here ➡️ doi.org/10.2337/dc26-1452
This infographic titled "Diabetes Care of Children With T1D at School" highlights a study on care location choices and glycemic control. It includes three main results: 1) Mean HbA1c levels by care location, showing classrooms have more favorable outcomes. 2) Dynamic age-dependent shifts showcasing changes at specific ages. 3) Identified predictors like insulin pump use. It notes a red restroom area as independently associated with higher HbA1c, while classrooms are associated with better management. The background lists study challenges, research question, and dataset details from a Japanese cohort. Implications suggest supporting students with structured diabetes care, ideally classroom-based.
November 3, 2026 at 2:20 PM
adapubs.bsky.social
The DASH4D diet significantly improved both blood pressure and blood sugar control. These data support making the DASH4D diet a recommended dietary pattern for patients with diabetes.

Read here ➡️ doi.org/10.2337/dc26-1159
The image is an infographic titled "The DASH4D Dietary Pattern for Better Diabetes Management." It consists of three columns: 1. Evidence Gap: Shows a cartoon person with food and a book labeled "ADA Standards of Care," stating that the ADA does not recommend a specific diet for people with diabetes. 2. Gold Standard Evidence: Displays a document titled "DASH4D Randomized Clinical Trial" and notes an 11.1 mg/dL reduction in mean glucose and a 5.2% increase in time in range, alongside a clock icon. 3. Recommendation: Features a cartoon person eating, with a book labeled "ADA Standards of Care," suggesting the DASH4D diet should be recommended for diabetes management, with an "Eat" and "Limit" section above showing food items.
October 31, 2026 at 1:15 PM
adapubs.bsky.social
Predictors of #T2D remission after metabolic surgery include shorter diabetes duration, fewer diabetes medications used, no insulin use, greater body weight, and weight loss at 1 year.

Read here ➡️ doi.org/10.2337/dc26-1070
This image is a flowchart comparing two interventions for Type 2 Diabetes and obesity. It describes a study with 262 participants, outlining age and BMI. Participants are randomly assigned to either Metabolic-Bariatric Surgery, which includes Sleeve Gastrectomy and Gastric Band, or Medical-Lifestyle Intervention. It highlights outcomes after 14 years of follow-up: 58% achieved diabetes remission with surgery, compared to 3% with lifestyle intervention. Predictors of diabetes remission and relapse are listed, focusing on duration of diabetes, medication use, and weight loss. "RYGB, Roux-en-Y Gastric Bypass" is noted at the bottom.
October 30, 2026 at 11:05 PM
adapubs.bsky.social
New #DiGest results show: low CHO was associated with improved glycemia, but micronutrient and fiber intakes were lower. No safety issues with low CHO diets were found but caution still needed.

Read here ➡️ doi.org/10.2337/dc26-0199
The image is an infographic summarizing the DiGest Trial on low-carbohydrate diets for gestational diabetes. It features three main sections: Methods, Results, and Conclusions. The Methods section includes information about a study of 215 pregnant individuals. The Results section compares outcomes for three carbohydrate intake levels: 6-8%, 45%, and nutritional considerations. The Conclusions emphasize caution and continued monitoring. Diabetes UK and DiGest logos are at the bottom.
October 28, 2026 at 3:55 PM
adapubs.bsky.social
Is your patient honeymooning? SEARCH study data show that the Insulin Dose-Adjusted HbA1c (IDAA1C) had poor performance in predicting C-peptide levels in youth with #type1diabetes

Read here ➡️ doi.org/10.2337/dc26-1313
Diagram illustrating a study on insulin dose-adjusted HbA1c performance among Type 1 Diabetes participants, from the SEARCH for Diabetes in Youth Study. It includes methods, hypothesis, sensitivity, and specificity graphs, with overall conclusions. BMI categorization and related data are highlighted.
October 27, 2026 at 1:00 PM
adapubs.bsky.social
Baseline clinical and biochemical characteristics cannot predict peak weight loss with semaglutide. Females using the highest dose of semaglutide (2.4 mg) in SELECT lost the most weight.

Read here ➡️ doi.org/10.2337/dc26-0784
A detailed infographic presenting study results on body weight loss with semaglutide treatment in the SELECT trial. It shows a graph of variability in weight loss by age and sex at week 5, with statistics in a table format. Key findings include time to peak body weight loss and the impact of age on weight reduction. The conclusion notes variations in effectiveness based on individual characteristics.
October 25, 2026 at 8:00 PM
adapubs.bsky.social
CGM-guided insulin optimization was associated with less nocturnal hyperglycemia and improved nutritional status in patients with chronic intestinal failure receiving parenteral nutrition.

Read here ➡️ doi.org/10.2337/dc26-0936
The image is an infographic titled "Continuous Glucose Monitoring–Guided Insulin Optimization in Patients Receiving Nocturnal Parenteral Nutrition." It has three main sections: Background, CGM-Guided Insulin Optimization, and Results. The background section describes chronic intestinal failure patients and hyperglycemia. The CGM section outlines insulin optimization with a focus on data analysis and individualized adjustments. The results section highlights improved glycemic control, noting significant percentage reductions in time spent in hypoglycemia, hyperglycemia, and increased time in range. A summary at the bottom states that this method improved metabolic control and nutrition.
October 23, 2026 at 7:20 PM
adapubs.bsky.social
A DASH-style diet significantly improves glucose control in adults with type 2 diabetes.

Read here ➡️ doi.org/10.2337/dc26-1062
An infographic titled "Effects of the DASH4D Diet on Biomarkers of Glycemia in Adults With Type 2 Diabetes" summarizes a clinical trial. It features three sections: "Question," "Study population," and "Results." The question asks about the DASH4D diet's effect on glycemia biomarkers. The study involves 101 adults with type 2 diabetes, average age 67, using DASH4D diet or standard diet for 4 months. Results show the DASH4D diet reduced fructosamine, glucose, and HbA1c levels. Bar graphs illustrate changes in fructosamine, fasting glucose, and HbA1c, highlighting significant differences.
October 22, 2026 at 9:00 PM
adapubs.bsky.social
One-third of adults with laboratory-confirmed diabetes lacked claims-documented diagnostic coding, treatment, or both, with patterns of care defined by glycemic severity and comorbidity burden.

Read here ➡️ doi.org/10.2337/dc26-1318

The image is an infographic about laboratory-confirmed diabetes diagnosis and treatment gaps. It states that one in three adults with confirmed type 2 diabetes has a gap in either diagnosis, treatment coding, or both. The infographic highlights that 27,650 adults were studied and breaks down the percentages related to gaps: 66.6% have no gaps, 19.1% have a diagnosis without treatment coding, 9.6% have treatment without a diabetes diagnosis, and 4.1% have gaps in both areas. Key findings emphasize higher HbA1c levels in those with any gaps. The conclusion suggests addressing coding gaps through better documentation.
October 21, 2026 at 3:45 PM
adapubs.bsky.social
The maternal effect in #T1D was not explained by underlying genetic susceptibility and waned after age 6, suggesting alternate mechanisms explain this early-life relative protection.

Read here ➡️ doi.org/10.2337/dc26-1524
The image presents a scientific poster titled "Relative Maternal Protection in Type 1 Diabetes Is Not Explained by Genetic Susceptibility and Affects Islet Autoimmunity (IA) Risk Until Age 6." It includes visual data and graphs: 1. A section showing offspring diabetes risk with figures illustrating different genetic relationships to Type 1 Diabetes (None, Sibling, Father, Mother). 2. A hypothesized genetic risk score (GRS) for offspring, with a diagram depicting protective factors for individuals listed as mothers. 3. A graph titled "No Difference in Offspring GRS2x" comparing genetic risk across relations. 4. A chart labeled "IA Risk Is Independent of GRS2x" with a plot tracking the development of autoimmunity risk over time. 5. A graph "Protection Wanes at Age 6" detailing how protection afforded by maternal factors decreases by age 6. Supporting text references data sources including the TEDDY study.
October 18, 2026 at 8:00 PM
mpp.org
Join us for a one-day conference on November 18 that pairs strategic networking with education on federal cannabis policy! Grab your tickets and check out the details: events.igniteit.com/dc26/registe...
October 16, 2026 at 7:32 PM
adapubs.bsky.social
An EHR-based Best Practice Advisory increased diabetes self-management education referrals nearly 10-fold and sustained gains for 18 months. Standing orders may help maintain referral momentum.

Read here ➡️ doi.org/10.2337/dc26-1213
Chart illustrating the impact of an electronic practice advisory on diabetes education referrals over 18 months. The image shows six clinics with patients eligible for diabetes education. An intervention group with 3,451 patients has 474 patients (13.7%) referred to education. A control group with 1,957 patients has 32 patients (1.6%) referred to education. The odds of referral are shown as 8.89 unadjusted and 9.44 adjusted. Key icons differentiate between intervention (with a document icon) and control (with a "no entry" symbol).
October 16, 2026 at 7:10 PM
adapubs.bsky.social
SGLT inhibitors have the potential to transform heart and kidney outcomes in #T1D. Here’s the roadmap to make it happen.

Read here ➡️ doi.org/10.2337/dc26-0999
This image is an infographic titled "Perspective: SGLT1 for Heart and Kidney Disease in T1D." It is divided into three main sections: 1. "Perspective on benefits" discussing therapeutic mechanisms, intermediate cardiovascular outcomes, and SGLT1 efficacy. 2. "Perspective on risks" highlighting DKA as the major risk, the need for education on ketone monitoring, and the importance of clinical trials. 3. "Conclusions" summarizing the balance of potential benefits and risks, including insights on pivotal trials and the importance of stakeholder discussions. Key terms include DKA, SGLT1, SGLT2, and T1D.
October 14, 2026 at 3:15 PM
adapubs.bsky.social
In adults with #T1D, 3-year CGM data showed distinct glycemic trajectories across high-risk subgroups, with substantial within-group variability—risk labels alone are insufficient.

Read here ➡️ doi.org/10.2337/dc26-1039
Chart titled "Three-year CGM trajectories highlight clinically relevant subgroup patterns in type 1 diabetes" displays data in three panels: Older age (≥65 years), CKD (eGFR <60 mL/min/1.73 m²), and β-cell failure (C-peptide <200 pmol/L). Each panel shows graphs of %TIR 70-180 mg/dL and %TBR <70 mg/dL over 36 months, with high-risk (orange) and reference groups (blue). Clinical implications summarized below each panel.
October 13, 2026 at 12:55 PM
adapubs.bsky.social
Higher BMI was associated with a higher prevalence of all CKM conditions, with
MASLD exhibiting the steepest association, followed by diabetes, HF, hypertension, ASCVD, and CKD.

Read here ➡️ doi.org/10.2337/dc26-1314
The image consists of two bar charts. Chart A, "Prevalence of BMI Categories," shows the percentage distribution of different BMI categories ranging from less than 25 to 40 or more. Chart B, "Number of CKM Conditions, by BMI Category," illustrates the percentage distribution of individuals with zero to three or more CKM conditions across various BMI categories.
October 12, 2026 at 6:00 PM
adapubs.bsky.social
CGM metrics capture risk of severe hypoglycemia and DKA in type 1 diabetes beyond HbA1c. A complementary approach to risk assessment. #CGM #T1D #Diabetes

Read here ➡️ doi.org/10.2337/dc26-1042
A diagram summarizing a study on continuous glucose monitoring metrics and the risks of severe hypoglycemia and diabetic ketoacidosis in type 1 diabetes. It includes three sections: Study Design, Glycemic Levels (CGM Metrics), and Outcomes & Findings. Study Design mentions 1,550 individuals, 10 studies, and 14-day metric collection. Glycemic Levels discuss time in range, variability, and metrics like TAR and TBR. Outcomes & Findings highlight links between TBR and severe hypoglycemia, and the association with diabetic ketoacidosis. A take-home message stresses the importance of CGM metrics and glycemic variability.
October 12, 2026 at 1:10 AM
hat-wearing.lucario.social
El lunes toca pasar tiradas de DC26 en el servidor de lobcorp 👍
October 9, 2026 at 6:36 PM
adapubs.bsky.social
Research shows mtDNA deletions cause 3% of unresolved syndromic diabetes. Routine screening via existing WGS data is recommended to increase diagnostic yield for free.

Read here ➡️ doi.org/10.2337/dc26-1211
Diagram representing human mitochondrial DNA (mtDNA). It features a circular map with sections labeled for control region, polypeptides, transfer RNA, and ribosomal RNA. Key genetic markers like MT-CYB, MT-ND1, MT-ND5, and MT-ND6 are indicated, along with amino acids and structural regions on L and H strands. Arcs depict overlapping gene regions.
October 10, 2026 at 6:55 PM